Dr. Glenn Wortmann, MD
Claim this profileMedStar Washington Hospital Center
Studies Coronavirus
Studies Coronavirus Disease
4 reported clinical trials
6 drugs studied
Area of expertise
1Coronavirus
diabetes
standard-of-care for COVID-19
SARS-CoV-2 virus
2Coronavirus Disease
Affiliated Hospitals
Clinical Trials Glenn Wortmann, MD is currently running
Phage Therapy
for Diabetic Foot Osteomyelitis
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
Recruiting0 awards Phase 28 criteria
hIVIG
for COVID-19
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that assesses the participant's clinical status seven days after the infusion of hIVIG or placebo. 1. Asymptomatic and no limitations in usual activity due to COVID-19 2. Mild COVID-19 illness or minor limitations to usual activity 3. Moderate COVID-19 illness and with major limitations to usual activity 4. Severe COVID-19 or serious disease manifestation from COVID-19 5. Critical illness from COVID-19 or Death Two strata of participants will be identified for analysis purposes. Stratum 2 will be participants who receive direct-acting antivirals (DAAs) or other anti-SARS-CoV2 agents that are approved/available and recommended for use as part of standard of care (SOC), estimated to be about 20% of participants. Stratum 1 will be participants who do not receive this agents, estimated to be about 80% of participants.
Recruiting1 award Phase 313 criteria
More about Glenn Wortmann, MD
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Glenn Wortmann, MD has experience with
- Placebo
- Hyperimmune Immunoglobulin To SARS-CoV-2 (hIVIG)
- LAU-7b
- Placebo Oral Capsule
- Phage Therapy
- Reparixin
Breakdown of trials Glenn Wortmann, MD has run
Coronavirus Disease
Osteomyelitis
Diabetic Foot
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Glenn Wortmann, MD specialize in?
Glenn Wortmann, MD focuses on Coronavirus and Coronavirus Disease. In particular, much of their work with Coronavirus has involved diabetes patients, or patients who are standard-of-care for COVID-19.
Is Glenn Wortmann, MD currently recruiting for clinical trials?
Yes, Glenn Wortmann, MD is currently recruiting for 3 clinical trials in Washington District of Columbia. If you're interested in participating, you should apply.
Are there any treatments that Glenn Wortmann, MD has studied deeply?
Yes, Glenn Wortmann, MD has studied treatments such as Placebo, Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), LAU-7b.
What is the best way to schedule an appointment with Glenn Wortmann, MD?
Apply for one of the trials that Glenn Wortmann, MD is conducting.
What is the office address of Glenn Wortmann, MD?
The office of Glenn Wortmann, MD is located at: MedStar Washington Hospital Center, Washington, District of Columbia 20010 United States. This is the address for their practice at the MedStar Washington Hospital Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.